Expanded indication to include pediatric patients from 6 - 17 years. Safety and effectiveness in this age group was established in an adequate and well-controlled trial.Safety and effectiveness in pediatric patients under 6 years of age have not been established.Efficacy and safety of treatment with more than one dose of Maxalt within 24 hours in patients 6 to 17 years of age have not been establishedMaxalt should not be prescribed to propranolol-treated pediatric patients who weigh < 40 kg (88 lb)The incidence of adverse reactions in the pediatric clinical trial was similar between treatment and placebo groups. The adverse reaction pattern in pediatric patients is expected to be similar to adultsHallucination, abnormal coordination, disturbance in attention, and presyncope occurred infrequently in pediatric patients in the clinical trial Information on dosing, adverse reactions, clinical trial, and overdose
|